keyword
MENU ▼
Read by QxMD icon Read
search

Surgery ovarian cancer

keyword
https://www.readbyqxmd.com/read/28430350/1st-evidence-based-italian-consensus-conference-on-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-carcinosis-from-ovarian-cancer
#1
Davide Cavaliere, Roberto Cirocchi, Federico Coccolini, Anna Fagotti, Massimiliano Fambrini, Orietta Federici, Domenica Lorusso, Marco Vaira, Marco Ceresoli, Paolo Delrio, Alfredo Garofalo, Sandro Pignata, Paolo Scollo, Vito Trojano, Andrea Amadori, Luca Ansaloni, Giuseppe Cariti, Franco De Cian, Pierandrea De Iaco, Michele De Simone, Marcello Deraco, Annibale Donini, Giammaria Fiorentini, Luigi Frigerio, Stefano Greggi, Antonio Macrì, Enrico Maria Pasqual, Franco Roviello, Paolo Sammartino, Cinzia Sassaroli, Giovanni Scambia, Carlo Staudacher, Patrizia Vici, Enrico Vizza, Mario Valle
Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015...
April 20, 2017: Tumori
https://www.readbyqxmd.com/read/28420521/delayed-postcoital-vaginal-cuff-dehiscence-with-small-bowel-evisceration-after-robotic-assisted-staging-surgery
#2
Yen-Po Lan, Huang-Hui Chen, Wei-Min Liu, Ching-Hui Chen
OBJECTIVE: We report a rare case of vaginal cuff dehiscence with small bowel evisceration at 7 months post robotic-staging surgery. CASE REPORT: A 41-year-old woman was sent to the emergency room with sudden onset of abdominal pain, vaginal bleeding, and vaginal protruding mass after sexual activity. She had a history of synchronous uterine and ovarian cancer treated with robotic-staging surgery 7 months before. Then she received six courses of postoperative adjuvant chemotherapy, and the last chemotherapy ended 1 month ago...
April 2017: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28418343/the-use-of-human-epididymis-4-and-cancer-antigen-125-tumor-markers-in-the-benign-or-malignant-differential-diagnosis-of-pelvic-or-adnexal-masses
#3
Zehra Nihal Dolgun, Canan Kabaca, Ateş Karateke, Cem İyibozkurt, Cihan İnan, Ahmet Salih Altıntaş, Cihan Karadağ
BACKGROUND: Ovarian cancer is one of the highest mortality cancers in gynaecology. Discrimination of benign masses from malignant ones may sometimes become a challenge for the clinician since there is not a reliable tumour marker, thus some unnecessary, highly morbid operations can be performed. AIMS: To explore the efficacy of human epididymis 4 (HE 4) and cancer antigen 125 (CA 125) markers in differentiating malignant and benign pelvic masses of ovarian origin and to identify the cut-off points for those markers...
April 5, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28415744/emt-like-circulating-tumor-cells-in-ovarian-cancer-patients-are-enriched-by-platinum-based-chemotherapy
#4
Issam Chebouti, Sabine Kasimir-Bauer, Paul Buderath, Pauline Wimberger, Siegfried Hauch, Rainer Kimmig, Jan Dominik Kuhlmann
BACKGROUND: Assuming that tumor cell dissemination requires a shift to a mesenchymal phenotype, we analyzed the incidence of epithelial-to-mesenchymal-transition (EMT)-like circulating tumor cells (CTCs) in ovarian cancer patients and inquired, how their molecular phenotypes respond to platinum-based chemotherapy and influence outcome. RESULTS: Before surgery, overall detection rate for epithelial CTCs was 18%. EMT-like CTCs were more frequently observed (30%) and were mutually exclusive to epithelial CTCs in the majority of patients (82%)...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414925/reversion-of-brca1-2-germline-mutations-detected-in-circulating-tumor-dna-from-patients-with-high-grade-serous-ovarian-cancer
#5
Elizabeth L Christie, Sian Fereday, Ken Doig, Swetansu Pattnaik, Sarah-Jane Dawson, David D L Bowtell
Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorable responses to chemotherapy. However, secondary intragenic (reversion) mutations that restore protein function lead to clinically significant rates of acquired resistance. The goal of this study was to determine whether reversion mutations could be found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in HGSC. Patients and Methods Plasma and tumor samples were obtained from 30 patients with HGSC with either BRCA1 or BRCA2 germline mutation...
April 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28411948/reporting-denominator-data-is-essential-for-benchmarking-and-quality-standards-in-ovarian-cancer
#6
Andrew Phillips, Janos Balega, James Nevin, Kavita Singh, Ahmed Elattar, Sean Kehoe, Sudha Sundar
OBJECTIVE: Combined surgery and platinum-based chemotherapy is the internationally agreed standard therapy for advanced ovarian cancer (AOC). However international cancer registry datasets demonstrate a significant proportion of patients do not receive both or either therapies. Our objective was to evaluate the effect of total patient cohort data ('Denominator') on median overall survival (OS) and determine how frequently this was reported in literature. METHODS: We retrospectively reviewed OS outcomes for 593 patients diagnosed with AOC for 77 months at a regional cancer centre...
April 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28407998/a-cost-effectiveness-evaluation-of-germline-brca1-and-brca2-testing-in-uk-women-with-ovarian-cancer
#7
Anthony Eccleston, Anthony Bentley, Matthew Dyer, Ann Strydom, Wim Vereecken, Angela George, Nazneen Rahman
OBJECTIVES: To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and second-degree relatives of BRCA mutation-positive individuals, compared with no testing. Female BRCA mutation-positive relatives of patients with ovarian cancer could undergo risk-reducing mastectomy and/or bilateral salpingo-oophorectomy. METHODS: A cost-effectiveness model was developed that included the risks of breast and ovarian cancer; the costs, utilities, and effects of risk-reducing surgery on cancer rates; and the costs, utilities, and mortality rates associated with cancer...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28407996/a-multigene-test-could-cost-effectively-help-extend-life-expectancy-for-women-at-risk-of-hereditary-breast-cancer
#8
Yonghong Li, Andre R Arellano, Lance A Bare, Richard A Bender, Charles M Strom, James J Devlin
BACKGROUND: The National Comprehensive Cancer Network recommends that women who carry gene variants that confer substantial risk for breast cancer consider risk-reduction strategies, that is, enhanced surveillance (breast magnetic resonance imaging and mammography) or prophylactic surgery. Pathogenic variants can be detected in women with a family history of breast or ovarian cancer syndromes by multigene panel testing. OBJECTIVES: To investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28406844/the-role-of-he4-a-novel-biomarker-in-predicting-optimal-cytoreduction-after-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer
#9
Francesco Plotti, Giuseppe Scaletta, Stella Capriglione, Roberto Montera, Daniela Luvero, Salvatore Lopez, Alessandra Gatti, Carlo De Cicco Nardone, Corrado Terranova, Roberto Angioli
OBJECTIVES: This study aimed to evaluate serum human epididymis protein 4 (HE4) changes during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff values and to demonstrate that CA125, HE4, and computed tomography (CT) taken together are better able to predict complete cytoreduction after NACT in advanced ovarian cancer patients. METHODS: From January 2006 to November 2015, patients affected by epithelial advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III-IV), considered not optimally resectable, were included in this prospective study...
April 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28406427/ten-important-considerations-for-ovarian-cancer-screening
#10
REVIEW
Edward J Pavlik
The unique intricacies of ovarian cancer screening and perspectives of different screening methods are presented as ten considerations that are examined. Included in these considerations are: (1) Deciding on the number of individuals to be screened; (2) Anticipating screening group reductions due to death; (3) Deciding on the duration and frequency of screening; (4) Deciding on an appropriate follow-up period after screening; (5) Deciding on time to surgery when malignancy is suspected; (6) Deciding on how screen-detected ovarian cancers are treated and by whom; (7) Deciding on how to treat the data of enrolled participants; (8) Deciding on the most appropriate way to assign disease-specific death; (9) Deciding how to avoid biases caused by enrollments that attract participants with late-stage disease who are either symptomatic or disposed by factors that are genetic, environmental or social; and (10) Deciding whether the screening tool or a screening process is being tested...
April 13, 2017: Diagnostics
https://www.readbyqxmd.com/read/28403964/-can-new-molecular-profiles-in-epithelial-ovarian-cancer-modify-therapeutics
#11
REVIEW
V Lavoué, A Rousselin, S Delplanque, M Pinsard, S Henno, F Foucher, J Levêque, T de la Motte Rouge
Epithelial ovarian cancer (EOC) affects 4500 women a year in France, with a survival of 30% at 5 years. Treatment is based on extensive surgery and chemotherapy. Around 15% of EOCs are due to genetic mutation predisposition essentially with mutated BRCA1 and BRCA2 genes. Four histological subtypes are described (serous, endometrioid, and mucinous cells to clear), corresponding to different carcinogenesis and distinct molecular mutations. High-grade serous EOCs have a mutation of the BRCA genes in 20-30% of cases...
February 2017: J Gynecol Obstet Hum Reprod
https://www.readbyqxmd.com/read/28399030/challenging-salpingectomy-as-a-risk-reducing-measure-for-ovarian-cancer-histopathological-analysis-of-the-tubo-ovarian-interface-in-women-undergoing-risk-reducing-salpingo-oophorectomy
#12
Chloe Ayres, Gayanie Ratnayake, Orla McNally, Michael Quinn
OBJECTIVE: Opportunistic bilateral salpingectomy is now promoted for women at the time of hysterectomy for a benign disease, consequent to the fimbrial end of the fallopian tube emerging as the primary site for carcinogenesis in high-grade serous carcinomas. In high-risk women with an identified germ line mutation, bilateral salpingo-oophorectomy offers the greatest risk reduction for ovarian cancer. Currently, no prospective evidence exists with respect to the effectiveness of opportunistic salpingectomy alone in preventing ovarian cancer...
April 8, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28395414/-clinical-application-of-robotic-plat-form-in-the-treatment-of-early-ovarian-cancer
#13
M X Ye, L Yu, W S Fan, M Wang, L H Bian, C L Gu, L Y Zhao, L A Li, Y G Meng
Objectives: To evaluate the feasibility and safety of robotic system in early ovarian cancer surgery. Methods: The clinical data of 131 patients with early ovarian cancer undergoing surgical treatment from November 2014 to November 2015 were reviewed retrospectively. There were 27 cases of early ovarian cancer, of which 9 cases of robotic group, 10 cases of laparoscopic group, 8 cases of laparotomy group. Age, Body Mass Index (BMI), preoperative neoadjuvant chemotherapy, operating time, operating method, intraoperative blood loss, intraoperative and postoperative complications, pathological type, lymph node dissection, postoperative exhaust time and postoperative hospital stay of all the patients were analyzed...
April 4, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28394545/parasitic-myoma-as-an-adnexal-mass-unexpected-finding-after-vaginal-hysterectomy
#14
Ratko Delić, Vladimir Weber
A rare case of parasitic myoma mimicking an adnexal mass in a previously hysterectomized, postmenopausal woman is presented. Two years after vaginal hysterectomy (due to myomas), an asymptomatic right adnexal tumor was noted during regular annual follow up. Ultrasound demonstrated a large 4-5 cm solid mass in the right adnexa, while ovarian cancer biomarkers (CA 125 and HE4) were negative. Intraoperatively, another 3 cm large solid tumor located above the vaginal cuff was discovered. Both pelvic tumors were excised by laparoscopic surgery...
June 2016: Acta Clinica Croatica
https://www.readbyqxmd.com/read/28390820/mortality-reduction-and-cost-effectiveness-of-performing-hysterectomy-at-the-time-of-risk-reducing-salpingo-oophorectomy-for-prophylaxis-against-serous-serous-like-uterine-cancers-in-brca1-mutation-carriers
#15
Laura J Havrilesky, Haley A Moss, Junzo Chino, Evan R Myers, Noah D Kauff
OBJECTIVE: To estimate the survival benefit and cost-effectiveness of performing hysterectomy during risk-reducing salpingo-oophorectomy (RRSO) for BRCA1 mutation carriers. METHODS: Based on a recent prospective cohort study indicating an elevated incidence of serous/serous-like uterine cancers among BRCA1 mutation carriers, we constructed a modified Markov decision model from a payer perspective to inform decisions about performance of hysterectomy during RRSO at age 40...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28389144/clear-cell-carcinomas-of-the-ovary-have-poorer-outcomes-compared-with-serous-carcinomas-results-from-a-single-center-taiwanese-study
#16
Fei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, Yun-Hsin Tang, Wei-Yang Chang, Jung-Erh Yang, Chun-Chieh Wang, Shih-Ming Jung, Cheng-Tao Lin, Ting-Chang Chang, Angel Chao, Chyong-Huey Lai
BACKGROUND/PURPOSE: To compare the clinical outcomes of Taiwanese patients with ovarian clear cell carcinomas (CCCs) and serous carcinomas (SCs). METHODS: We retrieved the clinical records of women with epithelial ovarian cancer (Stage I-IV) who received primary surgeries between 2000 and 2013. Cancer-specific survival (CSS), progression-free survival, and survival after recurrence (SAR) of CCC and SC patients were retrospectively compared. Multivariate analysis was used to identify the independent predictors of survival...
April 4, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28383367/laparoscopy-compared-with-laparotomy-for-debulking-ovarian-cancer-after-neoadjuvant-chemotherapy
#17
Alexander Melamed, Roni Nitecki, David M Boruta, Marcela G Del Carmen, Rachel M Clark, Whitfield B Growdon, Annekathryn Goodman, John O Schorge, J Alejandro Rauh-Hain
OBJECTIVE: To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer. METHODS: We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who underwent neoadjuvant chemotherapy and interval debulking surgery...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28382802/major-clinical-research-advances-in-gynecologic-cancer-in-2016-10-year-special-edition
#18
REVIEW
Dong Hoon Suh, Miseon Kim, Kidong Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS)...
May 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28382135/peripheral-blood-lymphocyte-to-monocyte-ratio-as-a-prognostic-factor-in-advanced-epithelial-ovarian-cancer-a-multicenter-retrospective-study
#19
Jia-Yu Zhu, Cheng-Cheng Liu, Liang Wang, Mei Zhong, Hai-Lin Tang, Hua Wang
The lymphocyte-to-monocyte ratio (LMR), as a surrogate marker of systemic inflammation, has been found to be a novel prognostic indicator in various malignancies. Data from 672 advanced epithelial ovarian cancer (EOC) patients treated with neoadjuvant chemotherapy (NAC) followed by debulking surgery were analyzed, and the prognostic value of LMR were evaluated. The optimal cutoff point of LMR in prediction of survival was defined as 3.45 through receiver operating characteristics curve analysis. Patients with low LMR (≤3...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28382099/fertility-rates-in-young-korean-breast-cancer-patients-treated-with-gonadotropin-releasing-hormone-and-chemotherapy
#20
Isaac Kim, Jai Min Ryu, Hyun-June Paik, Sungmin Park, Soo Youn Bae, Se Kyung Lee, Jonghan Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee
PURPOSE: Gonadotropin-releasing hormone (GnRH) agonists have been used with adjuvant chemotherapy to protect ovarian function. However, there are no data on the actual pregnancy rates among young breast cancer patients receiving GnRH agonists and concurrent chemotherapy in Korea. METHODS: Among patients who underwent surgery from January 2002 to April 2012, premenopausal patients aged between 20 and 40 years were included in the analysis. We retrospectively reviewed clinicopathologic features (e...
March 2017: Journal of Breast Cancer
keyword
keyword
55599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"